178 related articles for article (PubMed ID: 31682008)
1. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival.
Yilmaz M; Kantarjian H; Wang X; Khoury JD; Ravandi F; Jorgensen J; Short NJ; Loghavi S; Cortes J; Garcia-Manero G; Kadia T; Sasaki K; Konopleva M; Takahashi K; Wierda W; Jain N; Verstovsek S; Estrov Z; Bose P; Pierce S; Garris R; O'Brien S; Jabbour E
Am J Hematol; 2020 Feb; 95(2):144-150. PubMed ID: 31682008
[TBL] [Abstract][Full Text] [Related]
2. Real-world utility of early measurable residual disease assessments by multi-parametric flow cytometry in adult patients with B-lymphoblastic leukemia receiving Hyper-CVAD induction chemotherapy.
Nedumannil R; Ritchie D; Bajel A; Ng AP; Harrison SJ; Westerman D
Eur J Haematol; 2023 Feb; 110(2):168-176. PubMed ID: 36321745
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT.
Esteve J; Giebel S; Labopin M; Czerw T; Wu D; Volin L; Socié G; Yakoub-Agha I; Maertens J; Cornelissen JJ; Pigneux A; Shimoni A; Schwerdtfeger R; Labussière-Wallet H; Russell N; Schattenberg A; Chevallier P; Koza V; Foà R; Schmid C; Peric Z; Mohty M; Nagler A
Leukemia; 2021 Aug; 35(8):2232-2242. PubMed ID: 33542481
[TBL] [Abstract][Full Text] [Related]
4. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Jabbour E; Short NJ; Jorgensen JL; Yilmaz M; Ravandi F; Wang SA; Thomas DA; Khoury J; Champlin RE; Khouri I; Kebriaei P; O'Brien SM; Garcia-Manero G; Cortes JE; Sasaki K; Dinardo CD; Kadia TM; Jain N; Konopleva M; Garris R; Kantarjian HM
Cancer; 2017 Jan; 123(2):294-302. PubMed ID: 27602508
[TBL] [Abstract][Full Text] [Related]
5. [Minimal residual disease in adults with Philadelphia chromosome negative acute lymphoblastic leukemia in high-risk].
Li ZR; Zhao T; Liu YR; Wang YZ; Xu LP; Zhang XH; Wang Y; Jiang H; Chen YY; Chen H; Han W; Yan CH; Wang J; Jia JS; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):554-560. PubMed ID: 32397017
[No Abstract] [Full Text] [Related]
6. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.
Ribera JM; Oriol A; Morgades M; Montesinos P; Sarrà J; González-Campos J; Brunet S; Tormo M; Fernández-Abellán P; Guàrdia R; Bernal MT; Esteve J; Barba P; Moreno MJ; Bermúdez A; Cladera A; Escoda L; García-Boyero R; Del Potro E; Bergua J; Amigo ML; Grande C; Rabuñal MJ; Hernández-Rivas JM; Feliu E
J Clin Oncol; 2014 May; 32(15):1595-604. PubMed ID: 24752047
[TBL] [Abstract][Full Text] [Related]
7. Minimal Residual Disease at First Achievement of Complete Remission Predicts Outcome in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
Zhang M; Fu H; Lai X; Tan Y; Zheng W; Shi J; Zhao Y; Lin M; He J; Cai Z; Luo Y; Huang H
PLoS One; 2016; 11(10):e0163599. PubMed ID: 27695097
[TBL] [Abstract][Full Text] [Related]
8. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
[TBL] [Abstract][Full Text] [Related]
9. Satisfactory outcome after intensive chemotherapy with pragmatic use of minimal residual disease (MRD) monitoring in older patients with Philadelphia-negative B cell precursor acute lymphoblastic leukaemia: a Swedish registry-based study.
Bergfelt E; Kozlowski P; Ahlberg L; Hulegårdh E; Hägglund H; Karlsson K; Markuszewska-Kuczymska A; Tomaszewska-Toporska B; Smedmyr B; Åström M; Amini RM; Hallböök H
Med Oncol; 2015 Apr; 32(4):135. PubMed ID: 25796502
[TBL] [Abstract][Full Text] [Related]
10. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001.
Vrooman LM; Blonquist TM; Harris MH; Stevenson KE; Place AE; Hunt SK; O'Brien JE; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Neuberg DS; Sallan SE; Silverman LB
Blood Adv; 2018 Jun; 2(12):1449-1458. PubMed ID: 29941458
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of minimal residual disease measured by fusion-gene transcript in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated according to the MLL-Baby protocol.
Tsaur G; Popov A; Riger T; Kustanovich A; Solodovnikov A; Shorikov E; Demina A; Verzhbitskaya T; Streneva O; Makarova O; Lapotentova E; Aleinikova O; Miakova N; Boichenko E; Kondratchik K; Ponomareva N; Karachunskiy A; Roumiantsev A; Fechina L
Br J Haematol; 2021 Jun; 193(6):1151-1156. PubMed ID: 33583020
[TBL] [Abstract][Full Text] [Related]
12. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
Gökbuget N; Dombret H; Bonifacio M; Reichle A; Graux C; Faul C; Diedrich H; Topp MS; Brüggemann M; Horst HA; Havelange V; Stieglmaier J; Wessels H; Haddad V; Benjamin JE; Zugmaier G; Nagorsen D; Bargou RC
Blood; 2018 Apr; 131(14):1522-1531. PubMed ID: 29358182
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of minimal residual disease in young adults with standard-risk/Ph-negative precursor B-acute lymphoblastic leukemia: results of prospective study.
Salah-Eldin M; Abousamra NK; Azzam H
Med Oncol; 2014 May; 31(5):938. PubMed ID: 24692146
[TBL] [Abstract][Full Text] [Related]
14. Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL.
Wood B; Wu D; Crossley B; Dai Y; Williamson D; Gawad C; Borowitz MJ; Devidas M; Maloney KW; Larsen E; Winick N; Raetz E; Carroll WL; Hunger SP; Loh ML; Robins H; Kirsch I
Blood; 2018 Mar; 131(12):1350-1359. PubMed ID: 29284596
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance of CD20 Expression in Children with Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia.
Wang Y; Xue YJ; Jia YP; Zuo YX; Lu AD; Zhang LP
Acta Haematol; 2023; 146(5):349-357. PubMed ID: 37212472
[TBL] [Abstract][Full Text] [Related]
16. Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia.
Gökbuget N; Dombret H; Giebel S; Bruggemann M; Doubek M; Foà R; Hoelzer D; Kim C; Martinelli G; Parovichnikova E; Rambaldi A; Ribera JM; Schoonen M; Stieglmaier JM; Zugmaier G; Bassan R
Hematology; 2019 Dec; 24(1):337-348. PubMed ID: 30757960
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232.
Borowitz MJ; Wood BL; Devidas M; Loh ML; Raetz EA; Salzer WL; Nachman JB; Carroll AJ; Heerema NA; Gastier-Foster JM; Willman CL; Dai Y; Winick NJ; Hunger SP; Carroll WL; Larsen E
Blood; 2015 Aug; 126(8):964-71. PubMed ID: 26124497
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
[TBL] [Abstract][Full Text] [Related]
19. Post-induction Measurable Residual Disease Using Multicolor Flow Cytometry Is Strongly Predictive of Inferior Clinical Outcome in the Real-Life Management of Childhood T-Cell Acute Lymphoblastic Leukemia: A Study of 256 Patients.
Tembhare PR; Narula G; Khanka T; Ghogale S; Chatterjee G; Patkar NV; Prasad M; Badrinath Y; Deshpande N; Gudapati P; Verma S; Sanyal M; Kunjachan F; Mangang G; Gujral S; Banavali S; Subramanian PG
Front Oncol; 2020; 10():577. PubMed ID: 32391267
[No Abstract] [Full Text] [Related]
20. Clinical significance of end of induction measurable residual disease monitoring in B-cell acute lymphoblastic leukemia: A single center experience.
Arunachalam AK; Selvarajan S; Mani T; Janet NB; Maddali M; Lionel SA; Kulkarni U; Korula A; Aboobacker FN; Abraham A; George B; Balasubramanian P; Mathews V
Cytometry B Clin Cytom; 2023 Nov; 104(6):440-452. PubMed ID: 37555390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
